Immunome Stock Performance
| IMNM Stock | USD 22.54 1.00 4.64% |
On a scale of 0 to 100, Immunome holds a performance score of 5. The company retains a Market Volatility (i.e., Beta) of 1.21, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immunome will likely underperform. Please check Immunome's semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Immunome's current trending patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Immunome are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Immunome displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.02) | Five Day Return (2.22) | Year To Date Return 3.46 | Ten Year Return 60.15 | All Time Return 60.15 |
1 | Acquisition by Jack Higgins of 200000 shares of Immunome at 7.8 subject to Rule 16b-3 | 12/12/2025 |
2 | Acquisition by Clay Siegall of 46511 shares of Immunome at 21.5 subject to Rule 16b-3 | 12/18/2025 |
3 | Disposition of 11251 shares by Barchas Isaac of Immunome at 22.34 subject to Rule 16b-3 | 12/22/2025 |
4 | Is Immunome, Inc. The Best Booming Stock To Buy Right Now | 01/15/2026 |
5 | Immunome Hits New 12-Month High - Whats Next - MarketBeat | 01/22/2026 |
6 | Acquisition by Clay Siegall of 4729 shares of Immunome at 21.15 subject to Rule 16b-3 | 01/26/2026 |
7 | Immunome, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts - MarketBeat | 01/30/2026 |
8 | Acquisition by Boylan James P of 18864 shares of Immunome at 9.57 subject to Rule 16b-3 | 02/02/2026 |
9 | Acquisition by Bienaime Jean Jacques of 2000 shares of Immunome at 13.5699 subject to Rule 16b-3 | 02/03/2026 |
10 | Immunome to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 | 02/04/2026 |
11 | H.C. Wainwright initiates coverage on Immunome stock with Buy rating By Investing.com - Investing.com India | 02/12/2026 |
12 | Assessing Immunome Valuation After Recent Share Price Pullback | 02/23/2026 |
| Begin Period Cash Flow | 98.8 M | |
| Total Cashflows From Investing Activities | -85.1 M |
Immunome Relative Risk vs. Return Landscape
If you would invest 2,009 in Immunome on December 4, 2025 and sell it today you would earn a total of 244.50 from holding Immunome or generate 12.17% return on investment over 90 days. Immunome is currently generating 0.2879% in daily expected returns and assumes 4.49% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Immunome, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunome Target Price Odds to finish over Current Price
The tendency of Immunome Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 22.54 | 90 days | 22.54 | about 40.05 |
Based on a normal probability distribution, the odds of Immunome to move above the current price in 90 days from now is about 40.05 (This Immunome probability density function shows the probability of Immunome Stock to fall within a particular range of prices over 90 days) .
Immunome Price Density |
| Price |
Predictive Modules for Immunome
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immunome. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Immunome Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Immunome is not an exception. The market had few large corrections towards the Immunome's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immunome, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immunome within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.30 | |
β | Beta against Dow Jones | 1.21 | |
σ | Overall volatility | 2.30 | |
Ir | Information ratio | 0.07 |
Immunome Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immunome for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immunome can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Immunome had very high historical volatility over the last 90 days | |
| Immunome has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 9.04 M. Net Loss for the year was (292.96 M) with loss before overhead, payroll, taxes, and interest of (164.73 M). | |
| Immunome currently holds about 34.65 M in cash with (110.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86. | |
| Immunome has a very weak financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Assessing Immunome Valuation After Recent Share Price Pullback |
Immunome Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immunome Stock often depends not only on the future outlook of the current and potential Immunome's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immunome's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 58.6 M | |
| Cash And Short Term Investments | 217.3 M |
Immunome Fundamentals Growth
Immunome Stock prices reflect investors' perceptions of the future prospects and financial health of Immunome, and Immunome fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunome Stock performance.
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (21.37) % | ||||
| Current Valuation | 2.14 B | ||||
| Shares Outstanding | 110.34 M | ||||
| Price To Book | 9.13 X | ||||
| Price To Sales | 253.18 X | ||||
| Revenue | 9.04 M | ||||
| Gross Profit | (164.73 M) | ||||
| EBITDA | (151.35 M) | ||||
| Net Income | (292.96 M) | ||||
| Cash And Equivalents | 34.65 M | ||||
| Cash Per Share | 2.86 X | ||||
| Total Debt | 4.83 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.36 X | ||||
| Book Value Per Share | 2.88 X | ||||
| Cash Flow From Operations | (110.79 M) | ||||
| Earnings Per Share | (2.96) X | ||||
| Market Capitalization | 2.45 B | ||||
| Total Asset | 240.24 M | ||||
| Retained Earnings | (515.77 M) | ||||
| Working Capital | 167.03 M | ||||
About Immunome Performance
By examining Immunome's fundamental ratios, stakeholders can obtain critical insights into Immunome's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Immunome is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.33) | (0.35) |
Things to note about Immunome performance evaluation
Checking the ongoing alerts about Immunome for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunome help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunome had very high historical volatility over the last 90 days | |
| Immunome has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 9.04 M. Net Loss for the year was (292.96 M) with loss before overhead, payroll, taxes, and interest of (164.73 M). | |
| Immunome currently holds about 34.65 M in cash with (110.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86. | |
| Immunome has a very weak financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Assessing Immunome Valuation After Recent Share Price Pullback |
- Analyzing Immunome's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunome's stock is overvalued or undervalued compared to its peers.
- Examining Immunome's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunome's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunome's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunome's stock. These opinions can provide insight into Immunome's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Will Biotechnology sector continue expanding? Could Immunome diversify its offerings? Factors like these will boost the valuation of Immunome. Market participants price Immunome higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Immunome data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth 0.698 | Return On Assets | Return On Equity |
Understanding Immunome requires distinguishing between market price and book value, where the latter reflects Immunome's accounting equity. The concept of intrinsic value - what Immunome's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Immunome's price substantially above or below its fundamental value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Immunome's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.